

Technical Review Panel Member

Curriculum Vitae

Name: Damian Walker

Nationality: UK/USA (dual citizen)

Additional languages: French (intermediate)

Expertise: Health economics, health financing, health systems strengthening

Qualifications

Qualification	Institution	Department	Year
PhD	London School of Hygiene & Tropical Medicine	Global Health & Development	2006
MSc	University of York	Health Economics	1997
BSc	University of York	Economics	1996

Employment History

Employer	Position	Place	Year
Management Sciences for Health	Technical Director	Arlington, VA	2021-present
Center for Global Development	Non-Resident Fellow		2020-present
Bill & Melinda Gates Foundation	Deputy Director	Seattle, WA	2010-2019
Johns Hopkins University	Associate Professor	Baltimore, MA	2006-2010

London School of Hygiene & Tropical Medicine	Lecturer	London, UK	1997-2005
----------------------------------------------	----------	------------	-----------

Relevant Publications

1. Uy J, Siy Van VT, Ulep VG, Bayani DB, **Walker D**. The impact of COVID-19 on hospital admissions for twelve high-burden diseases and five common procedures in the Philippines: a national health insurance database study 2019-2020. *Lancet Reg Health West Pac*. 2022 Jan;18:100310.
2. Davis A, **Walker DG**. On the Path to UHC - Global Evidence Must Go Local to Be Useful Comment on "Disease Control Priorities Third Edition Is Published: A Theory of Change Is Needed for Translating Evidence to Health Policy". *Int J Health Policy Manag*. 2019 Mar 1;8(3):181-183
3. Robinson LA, Hammitt JK, Jamison DT, **Walker DG**. Conducting benefit-cost analysis in low-and middle-income countries: introduction to the special issue. *Journal of Benefit-Cost Analysis*, 2019; 10(S1), pp.1-14.
4. Chou VB, Bubb-Humfryes O, Sanders R, Walker N, Stover J, Cochrane T, Stegmuller A, Magalona S, Von Drehle C, **Walker DG**, Bonilla-Chacin ME, Boer KR. Pushing the envelope through the Global Financing Facility: potential impact of mobilising additional support to scale-up life-saving interventions for women, children and adolescents in 50 high-burden countries. *BMJ Glob Health*. 2018; 3(5): e001126.
5. Bocoum FY, Belemsaga D, Adjagba A, **Walker D**, Kouanda S, Tinto H. Malaria prevention measures in Burkina Faso: distribution and households expenditures. *Int J Equity Health*. 2014 Nov 7;13:108.
6. Wirtz AL, **Walker DG**, Bollinger L, Sifakis F, Baral S, Johns B, Oelrichs R, Beyrer C. Modelling the impact of HIV prevention and treatment for men who have sex with men on HIV epidemic trajectories in low- and middle-income countries. *Int J STD AIDS*. 2013
7. **Walker DG**, Walker GJ. Syphilis: still a major cause of infant mortality. *Lancet Infect Dis*. 2012 Apr;12(4):269
8. Maire N, Shillcutt SD, **Walker DG**, Tediosi F, Smith TA. Cost effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the Expanded Program on Immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria. *Value in Health* 2011;14(8):1028-38.
9. Shah M, Johns B, Abimiku A, **Walker DG**. Cost-effectiveness of new WHO recommendations for prevention of mother-to-child transmission of HIV in Nigeria. *AIDS*. 2011 May 15;25(8):1093-102.
10. **Walker DG**, Over M, Bertozzi SM. Can cost studies improve the performance of donor-financed HIV treatment? *AIDS*. 2011 Sep 10;25(14):1795-6.